FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2801783663> ?p ?o ?g. }

• W2801783663 endingPage "102" @default.
• W2801783663 startingPage "100" @default.
• W2801783663 abstract "Polycythemia vera (PV) is a Philadelphia-negative myeloproliferative neoplasm characterized by excessive myeloid cells production, mostly secondary to mutations in the Janus kinase 2 (JAK2) gene. PV natural history might be burdened by thrombotic events (TEs) and evolution into post-PV myelofibrosis (PPV-MF) or blast phase (BP). To date, no treatment strategies have been shown to have disease modifying effects, so therapy is directed at preventing TEs. All patients require phlebotomies (PHLs) to keep hematocrit below 45% and once-daily low dose aspirin (if not contraindicated). Apart from patients at “high risk” because of age over 60 years or a thrombosis history, cytoreductive therapies (CT) should be given to patients with relevant signs of myeloproliferation or intolerance to PHLs. Approved choices both for first and second line CT are hydroxyurea (HU) and pegylated forms of interferon (peg-IFN), the latter probably being better for young patients, and subjects without critical and recent vascular events or massive splenomegaly. The JAK1/2 inhibitor ruxolitinib is the treatment of choice in case of resistance/intolerance to HU, with proved efficacy in terms of thrombotic prevention. Data are too preliminary to consider CT for “low risk” PV cases, but ropeg-IFN is being studied in this setting with a short follow-up. A careful monitoring for signs of evolution into PPV-MF is fundamental for optimizing patient management." @default.
• W2801783663 created "2018-05-17" @default.
• W2801783663 creator A5000506070 @default.
• W2801783663 creator A5002133396 @default.
• W2801783663 creator A5008609620 @default.
• W2801783663 creator A5009381933 @default.
• W2801783663 creator A5013539196 @default.
• W2801783663 creator A5018111458 @default.
• W2801783663 creator A5018769277 @default.
• W2801783663 creator A5019208096 @default.
• W2801783663 creator A5026430732 @default.
• W2801783663 creator A5040941721 @default.
• W2801783663 creator A5046292780 @default.
• W2801783663 creator A5046772202 @default.
• W2801783663 creator A5052899068 @default.
• W2801783663 creator A5054304877 @default.
• W2801783663 creator A5055163444 @default.
• W2801783663 creator A5055401685 @default.
• W2801783663 creator A5065621786 @default.
• W2801783663 creator A5069072959 @default.
• W2801783663 creator A5072073030 @default.
• W2801783663 creator A5072484806 @default.
• W2801783663 creator A5073711573 @default.
• W2801783663 creator A5075657251 @default.
• W2801783663 creator A5082953818 @default.
• W2801783663 creator A5090834454 @default.
• W2801783663 creator A5091536542 @default.
• W2801783663 date "2018-06-01" @default.
• W2801783663 modified "2023-10-16" @default.
• W2801783663 title "Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia" @default.
• W2801783663 cites W2551080083 @default.
• W2801783663 cites W2620415343 @default.
• W2801783663 cites W2621352951 @default.
• W2801783663 cites W2746463998 @default.
• W2801783663 cites W2795763228 @default.
• W2801783663 doi "https://doi.org/10.1016/j.leukres.2018.04.012" @default.
• W2801783663 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29734070" @default.
• W2801783663 hasPublicationYear "2018" @default.
• W2801783663 type Work @default.
• W2801783663 sameAs 2801783663 @default.
• W2801783663 citedByCount "13" @default.
• W2801783663 countsByYear W28017836632019 @default.
• W2801783663 countsByYear W28017836632021 @default.
• W2801783663 countsByYear W28017836632022 @default.
• W2801783663 countsByYear W28017836632023 @default.
• W2801783663 crossrefType "journal-article" @default.
• W2801783663 hasAuthorship W2801783663A5000506070 @default.
• W2801783663 hasAuthorship W2801783663A5002133396 @default.
• W2801783663 hasAuthorship W2801783663A5008609620 @default.
• W2801783663 hasAuthorship W2801783663A5009381933 @default.
• W2801783663 hasAuthorship W2801783663A5013539196 @default.
• W2801783663 hasAuthorship W2801783663A5018111458 @default.
• W2801783663 hasAuthorship W2801783663A5018769277 @default.
• W2801783663 hasAuthorship W2801783663A5019208096 @default.
• W2801783663 hasAuthorship W2801783663A5026430732 @default.
• W2801783663 hasAuthorship W2801783663A5040941721 @default.
• W2801783663 hasAuthorship W2801783663A5046292780 @default.
• W2801783663 hasAuthorship W2801783663A5046772202 @default.
• W2801783663 hasAuthorship W2801783663A5052899068 @default.
• W2801783663 hasAuthorship W2801783663A5054304877 @default.
• W2801783663 hasAuthorship W2801783663A5055163444 @default.
• W2801783663 hasAuthorship W2801783663A5055401685 @default.
• W2801783663 hasAuthorship W2801783663A5065621786 @default.
• W2801783663 hasAuthorship W2801783663A5069072959 @default.
• W2801783663 hasAuthorship W2801783663A5072073030 @default.
• W2801783663 hasAuthorship W2801783663A5072484806 @default.
• W2801783663 hasAuthorship W2801783663A5073711573 @default.
• W2801783663 hasAuthorship W2801783663A5075657251 @default.
• W2801783663 hasAuthorship W2801783663A5082953818 @default.
• W2801783663 hasAuthorship W2801783663A5090834454 @default.
• W2801783663 hasAuthorship W2801783663A5091536542 @default.
• W2801783663 hasConcept C126322002 @default.
• W2801783663 hasConcept C170493617 @default.
• W2801783663 hasConcept C2776112149 @default.
• W2801783663 hasConcept C2777357209 @default.
• W2801783663 hasConcept C2778837598 @default.
• W2801783663 hasConcept C2779788118 @default.
• W2801783663 hasConcept C2780007613 @default.
• W2801783663 hasConcept C2780076729 @default.
• W2801783663 hasConcept C2781057849 @default.
• W2801783663 hasConcept C2781107747 @default.
• W2801783663 hasConcept C32465701 @default.
• W2801783663 hasConcept C71924100 @default.
• W2801783663 hasConcept C89560881 @default.
• W2801783663 hasConcept C90924648 @default.
• W2801783663 hasConceptScore W2801783663C126322002 @default.
• W2801783663 hasConceptScore W2801783663C170493617 @default.
• W2801783663 hasConceptScore W2801783663C2776112149 @default.
• W2801783663 hasConceptScore W2801783663C2777357209 @default.
• W2801783663 hasConceptScore W2801783663C2778837598 @default.
• W2801783663 hasConceptScore W2801783663C2779788118 @default.
• W2801783663 hasConceptScore W2801783663C2780007613 @default.
• W2801783663 hasConceptScore W2801783663C2780076729 @default.
• W2801783663 hasConceptScore W2801783663C2781057849 @default.
• W2801783663 hasConceptScore W2801783663C2781107747 @default.
• W2801783663 hasConceptScore W2801783663C32465701 @default.
• W2801783663 hasConceptScore W2801783663C71924100 @default.
• W2801783663 hasConceptScore W2801783663C89560881 @default.

• next